Welcome to our dedicated page for Teva Pharmaceutical Industries SEC filings (Ticker: TEVJF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Teva Pharmaceutical Industries's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Teva Pharmaceutical Industries's regulatory disclosures and financial reporting.
Teva Pharmaceutical Industries Limited submitted a Form 144 reporting proposed sales of ordinary shares through Citigroup Global Markets Inc., with transactions and vested compensation-related shares listed and one recent sale reported. The filing lists vested awards scheduled 03/03/2026 and a sale by Richard Francis on 02/17/2026 for 447,678 shares with amount 15324799.05.
Teva Pharmaceutical Industries disclosed a Form 144 notice reporting intended sales of ordinary shares. The filing lists restricted and performance share unit awards vesting on 03/03/2026 with quantities of 24,900, 110,668, and 30,810 shares tied to compensation awards. The broker listed is Citigroup Global Markets.
Teva Pharmaceutical Industries reports an insider Form 144 disclosing a sale of ordinary shares and upcoming compensation vesting. The filing shows 115,468 ordinary shares sold by Daniell Richard on 12/09/2025 for $3,311,131.04. The filing also lists compensation awards scheduled to vest on 03/03/2026: a Performance Share Unit award of 141,478 shares, Restricted Share Units of 24,900 shares, and Restricted Share Units (retention) of 37,350 shares.
Teva Pharmaceutical Industries Limited filed a Form 144 reporting proposed sales of ordinary shares. The filing lists proposed dispositions including 182,454 shares and 52,320 shares as examples, with the notice dated 02/26/2026. The entries are described as "shares from rollover" and "compensation" in the filing.
Teva Pharmaceutical Industries Ltd. filed an initial ownership report for interim Chief Legal Officer Brian Savage, detailing his existing equity awards and share holdings. The filing lists direct holdings of stock options, multiple tranches of restricted share units with specified vesting schedules through 2029, and ordinary shares that may be represented by American Depositary Shares. It does not record any new purchases or sales, but simply discloses current positions and how and when they vest into ordinary shares or cash.
Teva Pharmaceutical Industries’ President and CEO, Richard Francis, reported a combination of share exercises and sales. On February 15, 2026, he exercised restricted share units into ordinary shares and then sold a total of 447,778 ordinary shares at a weighted average price of $34.2241 per share, in multiple trades between $34.015 and $34.51.
The transactions were carried out under a Rule 10b5-1 trading plan adopted on November 14, 2025. Footnotes state that some of the vested shares, including performance-based awards, were sold to cover tax withholding obligations. After these moves, he directly owned 605,771 Teva ordinary shares.
Teva Pharmaceutical Industries Limited filed an amendment to a Rule 144 notice that lists proposed disposition of 447,778 ordinary shares through Citigroup Global Markets. The amendment also lists 161,656 restricted share units and 620,110 performance share units, each dated 02/15/2023, with an entry date of 02/17/2026.
TEVA Pharmaceuticals filed a Form 144 reporting the planned sale of 447,778 ordinary shares. The filing lists Citigroup Global Markets Inc. as the broker and shows the transaction date 02/17/2026 on the NYSE. The filing also lists restricted share unit and performance share unit award amounts of 161,656 and 620,110 respectively, both with an award date of 02/15/2023.
Migdal Insurance & Financial Holdings Ltd. filed a Schedule 13G reporting beneficial ownership of 61,689,363 Teva Pharmaceutical Industries Ltd. ordinary shares, representing 5.37% of the class, based on 1,149,812,898 shares outstanding as of December 31, 2025.
The shares are held through various Migdal subsidiaries that manage insurance, pension, provident, mutual fund and portfolio accounts, each under independent management. As of January 20, 2026, the filing lists 107,000 shares held by Migdal Insurance Company Ltd., 53,935,231 shares by Migdal Sal Domestic Equities, and 7,647,132 shares by Migdal Mutual Funds Ltd.
The filing emphasizes that these securities are not held to change or influence control of Teva and that Migdal and its subsidiaries disclaim beneficial ownership beyond their actual economic interest.
Harel Insurance Investments & Financial Services Ltd filed an amended Schedule 13G reporting beneficial ownership of 72,325,555 Teva Pharmaceutical Industries Ltd ordinary shares, representing 6.3% of the class based on 1,149,812,898 shares outstanding as of December 31, 2025.
Harel explains that 70,039,163 shares are held for public investors through various funds and insurance products managed by its subsidiaries, 1,090,246 shares are held in third-party client accounts, and 1,196,146 shares are held for its own account. Harel disclaims beneficial ownership of more than the 1,196,146 shares held for its own account.
The filing shows Harel has no sole voting or dispositive power, with shared voting power over 71,235,309 shares and shared dispositive power over 72,325,555 shares. Harel certifies the holdings are not for the purpose of changing or influencing control of Teva.